News

With the number of cancer survivors expected to reach 19 million by 2024, how these individuals fare long-term is an issue of ongoing interest and concern. An analysis of findings from a large survey of survivors conducted by the American Cancer Society (ACS) has found that many survivors continue to face physical, mental, and financial difficulties long after their treatment ends.

Changing the administration schedule for gemcitabine plus nab-paclitaxel (Abraxane) from weekly to every other week significantly reduced side effects without impacting efficacy as a frontline treatment for patients with metastatic pancreatic cancer, according to a retrospective study presented at the 2015 GI Cancers Symposium.

The American Association for Cancer Research (AACR) and the American Society of Clinical Oncology (ASCO) have collaborated on an outline that would help policymakers regulate electronic cigarettes and other electronic nicotine devices (ENDS) without undermining their potential as a smoking cessation tool, the two cancer organizations announced.

While managing cancer risk is a priority, BRCA mutation carriers are often concerned about their risk of heart disease-the leading cause of death for American women-and how their mutation or risk-management choices may impact their cardiovascular health.

The FDA has approved the PARP inhibitor olaparib (Lynparza) for the treatment of women with BRCA-positive advanced ovarian cancer. The approval was based on results from a single-arm phase II study of patients with deleterious or suspected deleterious germline BRCA-mutated advanced cancers